PAPAyA: A Highly Scalable Cloud-based Framework for Genomic Processing

Francois Andry¹, Nevenka Dimitrova², Alexander Mankovich², Vartika Agrawal², Anas Bder³ and Ariel David³

¹Philips, HISS, 4100 East Third Ave, Foster City, U.S.A.
²Philips, CISS, 19 Skyline Drive, Hawthorne, U.S.A.
³Philips, HISS, 18 Aharon Bart St, Petah Tikva, Israel

Keywords: Genomics, Cloud, PaaS, IaaS, Security, Privacy, Asynchronous Processing, Pipelines, Workflow, Big Data, Analytics, NGS, Oncology, Infectious Diseases.

Abstract: The PAPAyA platform has been designed to ingest, store and process in silico large genomics datasets using analysis algorithms based on pre-defined knowledge databases with the goal to offer personalized therapy guidance to physicians in particular for cancers and infectious diseases. This new highly scalable, secure and extensible framework is deployed on a cloud-based digital health platform that provides generic provisioning and hosting services, identity and access management, workflow orchestration, device cloud capabilities, notifications, scheduling, logging, auditing, metering as well as specific patient demographic, clinical and wellness data services that can be combined with the genomics analytics results.

1 INTRODUCTION

Progress in next-generation sequencing (NGS), including whole genome and exome sequencing, transcriptome profiling and detection of single nucleotide polymorphisms (SNPs), together with innovations in cloud-based architectures and big-data analytics stacks is unlocking the power of genomes towards personalization of healthcare.

There are multiple clinical areas, such as oncology, infectious diseases, clinical genetics and others, where genomics can have big impact on clinical decision-making.

In oncology, it is well known that tumors are driven by the accumulation of numerous molecular alterations. In this case, the care for the patient can be personalized: based on the patient genomic fingerprint and other sources of information (e.g. radiology, biopsy, clinical data, family history and population management data), new therapy options and clinical trials can be proposed by an oncologist.

When it comes to infectious diseases, the genomic sequence can help characterize the precise sub-strains of a particular pathogen and reveal any inherent resistance it may have to antibiotics. This is important in molecular epidemiology especially in the light of the emergence of so-called superbugs that can spread as hospital acquired infections.

To address these applications, we started with a prototype: Physician Accessible Personalized Analytics Application (aka PAPAyA) for research in breast cancer that relies on multiple genomics modalities: gene expression and differential DNA methylation. The application was oriented towards a patient centric interpretation of microarray data and biomarker (signature) discovery.

However, with the evolution of genomics and introduction of next generation sequencing, the amount of input data increased many-fold and there was a need for more versatile platform to address different types of cancer, and allow for building clinical applications in various disease domains such as infectious diseases and cardiology.

The initial prototype was to present the concept of a research platform for biomarker discovery and decision support in breast cancer (Janevski et al., 2009).

The focus of the current platform in this paper is to enable full scalable cloud based architecture and implementation to support extensibility, reliability, security and use it for any cancer and any biological or clinical domain. Another dimension of the new platform is the versatility to handle any analysis of next generation sequencing data (expression, copy

Andry, F., Dimitrova, N., Mankovich, A., Agrawal, V., Bder, A. and David, A.
DOI: 10.5220/0005668401980206
ISBN: 978-989-758-170-0
Copyright © 2016 by SCITEPRESS – Science and Technology Publications, Lda. All rights reserved
In this paper we describe how the Philips PAPAyA has been designed to associate genomic data with clinical data while leveraging the power of our PaaS: HealthSuite Digital Platform (HSDP) in order to process genomic data and be able to provide precision diagnostic, for example, the following questions:

- How to match a tumor’s genotype with a drug for best outcome?
- How to elucidate the cancer subtypes in a set of RNAseq samples?
- How to tackle and prevent the spread of hospital acquired infections?

However, converting high-throughput genomic data into clinically actionable information is not a straightforward task.

The first challenge is to be able to ingest and store extremely large amounts of genomic data (up to 1TB for a single patient whole genome) in a reliable and secure manner while satisfying legal requirements for long-term storage.

The second challenge is to be able to run asynchronously parallel processing heterogeneous pipelines and associated jobs (e.g. sequence alignment, variant and mutation calling, copy number variation detection), written in various programming languages, in a highly quality controlled, reliable, reproducible and scalable manner.

The third challenge is to dynamically integrate domain-specific knowledge from various databases that may require frequent updates and to generate clinically actionable results that are reproducible during subsequent runs.

A fourth difficulty is to manage the potential users of the platform (researchers, oncologists, pathologists, physicians, technicians, administrators) and to create an interactive, role-based and secure user interface that provides several key functions: to query the framework; to display the data, metadata and knowledge-bases used; to define and obtain the definition of pipelines and modules; to retrieve the output of the tools; and to generate an intuitive and comprehensive visualization of reports and analytics.

There have been many efforts to automate next generation sequencing data analysis. Galaxy is such a workflow system that has been used in sequence analysis and other bioinformatics applications (Goecks et al., 2012).

Another group developed infrastructure and tools to support multisite comparative effectiveness studies using web services for multivariate statistical estimation in the SCANNER federated network. (Meeker et al., 2015).

While these public efforts are excellent vehicles for research activities, they are not meant for using in clinical applications.

GenePattern was one of the first systems that offered to a broad audience a repository of analytic tools for genomic data (Reich et al., 2006).

Focusing on the web access, Mobyle system offered a large panel of curated bioinformatics tools available in a homogeneous environment, to invoke services distributed over remote Mobyle servers, thus enabling a federated network of curated bioinformatics portals without the user having to learn complex concepts or to install sophisticated software (Néron et al., 2009).

## 2 USE CASES

PAPAyA is a framework, deployed on the HealthSuite Digital Platform, for hosting multiple genome informatics applications. These applications inhabit diverse clinical domains and assemble information from various sources, across many hospitals and their affiliates either on premise or on the cloud, and can deliver real-time actionable information to the clinical experts.

Examples of use cases include breast, prostate and lung cancer scenarios with oncologists, pathologists, urologists, and genome informaticists as users.

## 3 SYSTEM SPECIFICATIONS

In redesigning the PAPAyA architecture, our team always had in mind to build a world-class platform with the following intrinsic properties:

- **Reliability:** Offers dependable mechanisms for automatic, secure, quality assured acquisition of demographic, clinical and genomic data from healthcare organizations. Provide a reliable way to schedule and execute various pipelines such as those for detecting variants, mutations, copy number variation (CNV), differential gene expression and differential DNA methylation.
- **Security:** Creates and manages user accounts with highly secure authentication and authorization mechanisms, and encrypted data in flight, but also at rest (including secure
Table 1: PAPAyA cancer related usage scenarios.

<table>
<thead>
<tr>
<th>Patients history/context</th>
<th>PAPAyA process/output</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient is 63 years old, diagnosed with primary localized prostate cancer. Biopsy shows a Gleason score of 3 (moderately differentiated carcinoma). Urolologist wants to know the aggressiveness of the tumor and options for any surgical procedures, chemotherapy or active surveillance.</td>
<td>Patient's RNA is extracted from the patient tissue and PAPAyA runs the RNAseq pipeline. Assessment of tumor-driving cancer signalling pathways indicates that the patient does not have an aggressive disease. The urologist may suggest a simple follow up without immediate intervention.</td>
</tr>
<tr>
<td>Patient is 48-year-old woman with a distant history of light smoking who has been diagnosed with stage IV lung carcinoma and has already started chemotherapy. However, her condition has recently deteriorated: fluid output from a right pleural catheter, fatigue, weight loss, hypoxemia, fever and hypercalcemia. Oncologist is considering using a targeted therapy as an alternative.</td>
<td>Patient RNA transcriptome sequencing is ordered. PAPAyA analysed the sequencing data and whole exome revealed several fusions (such as EML4-ALK). This information along with radiology and pathology is presented. The genomic information points to efficient drugs specifically targeting these fusions (Crizotinib), and the doctor may propose a few related clinical trials targeting the EML4-ALK fusion.</td>
</tr>
<tr>
<td>New renal cell carcinoma patient study is already underway and the principal investigator needs to process RNAseq data and exome data.</td>
<td>PAPAyA analysed the sequencing data using whole transcriptome detection, quantification pipeline, exome alignment and variant calling.</td>
</tr>
<tr>
<td>New renal cell carcinoma study is underway and the Principal investigator is interested in figuring out which patients have good prognosis and what are the set of genes (signature) that stratifies for best outcome.</td>
<td>PAPAyA enabled analysis of the quantified RNAseq data to derive a new signature for prognosis of different subtypes of renal cell tumors using unsupervised learning (including deep learning methods), statistical evaluation and differential survival analysis.</td>
</tr>
<tr>
<td>Multiple RNAseq studies are available for study to a researcher who is looking for biomarker positive or signature positive patients in order to create a clinical study or enroll patients in a clinical study.</td>
<td>Cohort analysis within PAPAyA is conducted with run-time execution of &quot;missions&quot; which include genomic pipelines and analytics in a cohort discovery mode, evaluate classification methods like random forests for patient selection (through inverted matrices).</td>
</tr>
</tbody>
</table>

Table 2: PAPAyA infectious disease scenario.

<table>
<thead>
<tr>
<th>Patients history/context</th>
<th>PAPAyA process/output</th>
</tr>
</thead>
<tbody>
<tr>
<td>More than 50% of patients in a 26-patient ward of a public hospital have been infected with Methicillin-resistant Staphylococcus aureus (MRSA). From the resulting genomic analysis, a phylogenetic tree of the pathogen SNP data is derived, to determine clusters of close genetic relatedness and a possible transmission route. Gene classification for each sub-sub-strain and associated drug resistances can help identify possible treatment.</td>
<td>Swabs are collected from each patient and sent to PAPAyA for sequencing the DNA of the pathogens. The hospital institution wants to determine the source of the outbreak.</td>
</tr>
</tbody>
</table>

3.1 Data Acquisition

The PAPAyA platform must not only import and manage new genomic data delivered from NGS hardware residing in the hospital or at a service lab, but also patient demographic and clinical data (e.g. from an EMR), pathology and histological data from the Laboratory Information Management System (LIMS) and optionally radiology information from a Radiology Information System (RIS).

3.1.1 Genomic Data

Genomic input data coming from sequencers (bar-coded genomic data) will need to be moved to a database for storing the raw data (FASTQ format), short- and long-term storage for raw and analysed genomic data.

- **Reproducibility:** Requires that running a mission with identical inputs (data and knowledge-bases) produce the same results. It must also record all specific versions of algorithms and databases used for each sample processed.
- **Extensibility:** Creates workflows for new health care domains where genomics can be applied. Enables the ability to create new mission cohorts, add new and up-to-date genomic and medical knowledge bases, as well as create new access points for advanced research and clinical trials.
- **Scalability:** Builds new distributed instances of the pipelines and workflows that can meet sudden demand increase.
- **Compliance:** Maintains compliance with HIPAA, HITECH, 21 CFR part 11.
processed data (BAM format, VCF format) and all the metadata associated with the various steps of library preparation, sequencing and analysis.

Table 3: Genomic data storage requirements.

<table>
<thead>
<tr>
<th>Data type</th>
<th>Raw data</th>
<th>Processed data</th>
</tr>
</thead>
<tbody>
<tr>
<td>whole genome</td>
<td>0.5-1 TB</td>
<td>1-2 TB</td>
</tr>
<tr>
<td>whole transcriptome</td>
<td>10-20 GB</td>
<td>20-40 GB</td>
</tr>
<tr>
<td>targeted transcriptome</td>
<td>1-4 GB</td>
<td>4-8 GB</td>
</tr>
<tr>
<td>targeted, 500 translocations</td>
<td>4-8 GB</td>
<td>8-16 GB</td>
</tr>
<tr>
<td>whole exome</td>
<td>20-40 GB</td>
<td>40-80 GB</td>
</tr>
<tr>
<td>targeted exome, 500 genes</td>
<td>4-8 GB</td>
<td>8-16 GB</td>
</tr>
</tbody>
</table>

3.1.2 Other Patient Data

Demographic and clinical data from EMRs and other various clinical systems, including pathology and radiology data from the patient (in HSDB done via a VHR and an associated EMPI), is imported, reconciled and associated with biological sequencing data. We can potentially implement the enterprise master patient index (EMPI) across multiple organizations. Our Virtual Health Record (VHR) is capable of extracting and repurposing data from multiple different EMR systems (e.g. EPIC, Cerner and others).

To ensure interoperability, we implement data standardization aspects following HL7, NAACCR, CCR, CDA and CCD specifications. We are also closely involved with GA4GH to keep up with the various discussions and developments in the working groups.

3.2 Defining Pipelines and Modules

Pipelines used in PAPAyA are defined as a sequence of standard jobs (i.e., series of steps embodying bioinformatics tools and commands) used to transform data (e.g. sequencing data in FASTQ format) from a raw state to a processed state in which various analyses can be performed on variant calling data in VCF format (Danecek et al. 2011).

Our first pipelines include the steps that help the creation of phylogenetic tree for infectious diseases and exome based pipelines for oncology.

The flexible design enables incorporation of a new cancer signature or a new phylogeny building method to be added.

The modules are implemented using univariate or multivariate statistical methods as well as various machine learning and computational biology algorithms. For example, cancer subtyping can be a specific module that leverages unsupervised learning capabilities of the analytics platform.

The distinction that we make is that the role of modules is to answer specific clinical questions while pipelines perform computationally intensive processing that generate intermediate results used as input to modules themselves.

Certain modules include genomics-oriented analytics, as well as NLP-related analytics. Our clinical trial matching module relies upon a well proven NLP engine that has parsing, tokenizing capabilities and leverages ontologies such as SNOMED and LOINC.

3.3 Defining Missions

The highest level of operation within PAPAyA is accomplished with the concept of “missions”. A mission is a run time construct that defines several parameters in a workflow:
- Sample or list of samples
- Raw, intermediate, or processed genomic data
- Pipelines and/or analytics Modules and any relevant input parameters
- Cohort identification
- Visualizations of complex genomic data
- Querying and Visualizations of integrated patient and genomic data

The mission is then executed to obtain a desired output such as performing cohort survival analysis on a set of patients and returning Kaplan-Meier curve data. It can also be re-run with identical or new inputs such as updated pipelines or tools.

A mission can also encompass multiple modules so that computational biology workflows can be automated – for example, searching for the most optimal number of genes that increases the difference between survival curves of patient subgroups.

Missions seamlessly enable flexible task execution, detailed process documentation (for any retrospective data auditing), and universal applications for data from infectious disease, oncology.
3.4 Running Asynchronous Jobs

Running a large diversity of genomics tools associated with pipelines and modules (C, C++, Java, Perl, Ruby, Python, R) asynchronously in parallel and at scale requires the platform to be able to:

- provision and host the variety of jobs and their ecosystems dynamically on demand,
- schedule and run these jobs as part of pre-defined workflows asynchronously,
- pass parameters and results that are output between jobs,
- check the status and progress of jobs,
- cancel and retry specific jobs,
- isolate jobs and associated data for each specific tenant

3.5 Super Users

PAPAyA provides its users the ability to define missions and workflows and design their own pipelines based on the available tools.

It also allows them to monitor the current processes that are being executed and alerts them to any errors that may result from substandard input data.

While there are default pipelines and workflows predesigned in the system, the software enables users to customize pipelines by mix-and-match of tools.

3.6 Genomic Knowledge Bases

The final and one of the most important aspects of genomic analysis is the interpretation of the genomic results in a functional and/or a clinical context.

For example, when analysing variants for patients, it is important to identify causal/driver mutations or clinically actionable variants. In order to do this, a comprehensive data repository has to be created that can be used efficiently to annotate genomic aberrations/alterations (variants, mutations, CNVs, gene fusions).

This repository is created by integrating various publicly available data sources such as dbSNP, Refseq etc. Another important source of clinical information is the vast pool of literature available on PubMed.

The entire scientific community is contributing to this source at an unprecedented level. Using a blend of natural language processing (NLP) and manual curation of data can help us extract meaningful genotype-clinical associations which in turn can help make valuable inferences for the patients’ response/prognosis.

The variant annotation repository of PAPAyA incorporates all the above-mentioned sources to annotate aberrations at four levels and thus place the genomic results in a clinically relevant context.

3.7 Decision Support

Multiple levels of decision support are feasible on the platform starting with the replacement of the so-called IVD tests for single genes (for example, assessment of the mutation status of the BRAF or the EGFR gene). We have developed the concept of in-silico assays and the workflows on the platform are intended to support both clinical practice.

- Executing already validated biomarkers (signatures) as in-silico assays which take certain cohort patient characteristics, genomic/transcriptomic data and a decision function in order to make an inference.
- Applying signatures as in-silico assays for cancer subtyping within an organ based on classification of tumors as well as pan-cancer. An example would be breast cancer subtyping into Luminal A, Luminal B, Her2, and basal tumors based on a set of 50 genes. Similar
types of signatures have been used for brain, ovarian, renal cell carcinoma and others.

- Applying predictive signature that can determine the probability of response to a certain drug.

3.8 Clinical Research

On the clinical and pharma research side, we envision support for workflows such as:

- Discovery of signatures based on whole transcriptome data as well as multimodality signatures leveraging the fact that the platform has access to genomic, transcriptomic and methylation data.
- Multimodal pathway evaluation in a neoadjuvant setting to determine the effect of a certain drug or combination of drugs on the signalling pathways perturbed by the therapy.
- Using genome analytics combined with machine learning to develop signatures encompassing stratification/subtyping for best outcome, prediction to response, prognosis, and inference of candidates to clinical trials.

4 ARCHITECTURE

The PAPAyA platform is composed of the following distinct subsystems:

- Public Gateway Services: a REST API exposing all underlying functionalities to be consumed by PAPAyA front-end application components.
- Genomic Data Persistence: configuration, data acquisition, read/write operations.
- Genomics Pipelines & Modules Processing: configuration, scheduling, execution and monitoring.
- User Management: user registration (register a new user account, update profile information, change and reset password information), authenticate a user and validate user access token.

In addition the platform is using the Philips HealthSuite Digital Platform (HSDP) foundation services for storage, job execution, user management and other basic infrastructure functions (Andry et al., 2015).

4.1 Public Gateway Services

The public gateway services form a thin layer exposing the public PAPAyA HSDP API for integration. This layer serves a system entry-point supplying a client with a public REST interface. The main logic of the public web services is only to be a functional secure bridge between public and internal APIs (data and metadata persistence, configuration, monitoring, user management).

Figure 3: PAPAyA deployment architecture.

4.2 Genomic Data Persistence Services

The genomic data persistence API service is responsible for managing genomic data and associated metadata including:

- **Create/Update Data**: an interface for saving any genomic data, including raw data and pipeline intermediate results. The user may specify additional user-defined metadata for the file such as batch ID. Asynchronous uploads of large files is also offered. The user specifies the location of the data and the service will copy the data to the persistence and provide a transaction ID for follow-up.
- **Read Data**: retrieve data from the persistence according to a specified filter (name, type, pipeline step). API operations are also available to check the status of an upload request. The response will return the state of the copy and additional metadata.

This internal REST API encapsulates two sets of services: the genomic data persistence API itself and an associated configuration API and back-end façade integration components: genomic metadata persistence data access object (DAO) and genomics HSDP storage adapter that decouple the business
logic of the API and the actual databases.

Figure 4: PAPAyA genomic data persistence services.

4.3 Genomics Processing Module

The genomics processing module is at the heart of PAPAyA. It includes the following REST APIs:

- Genomic processing configuration: to define, upload, schedule, run or cancel the executions of missions and associated modules and pipelines steps and jobs.
- Genomic processing monitoring: to get the status of the execution of missions, modules and pipelines.
- Genomic knowledge database services: to update or query the genomic knowledge bases used by the pipelines or the execution of clinical missions.

Table 4: Genomic processing API operations subset.

<table>
<thead>
<tr>
<th>Operations description</th>
<th>API</th>
<th>Path</th>
</tr>
</thead>
<tbody>
<tr>
<td>Create a module</td>
<td>POST</td>
<td>https://&lt;host&gt;/.../modules/{module-id}</td>
</tr>
<tr>
<td>Retrieve a module</td>
<td>GET</td>
<td>.../.../modules/{module-id}</td>
</tr>
<tr>
<td>Create a pipeline</td>
<td>POST</td>
<td>.../.../pipelines/{pipeline-id}</td>
</tr>
<tr>
<td>Retrieve a pipeline</td>
<td>GET</td>
<td>.../.../pipelines/{pipeline-id}</td>
</tr>
<tr>
<td>Create a mission</td>
<td>POST</td>
<td>.../.../missions/{mission-id}</td>
</tr>
<tr>
<td>Retrieve all missions</td>
<td>GET</td>
<td>.../.../missions</td>
</tr>
<tr>
<td>Launch a mission</td>
<td>POST</td>
<td>.../.../missions/{mission-id}/sequences/{sequence-id}/executions</td>
</tr>
<tr>
<td>Cancel the execution of a mission</td>
<td>DELETE</td>
<td>.../.../missions/{mission-id}/executions/{execution-id}</td>
</tr>
<tr>
<td>Cancel the execution of a mission</td>
<td>DELETE</td>
<td>.../.../missions/executions/{execution-id}</td>
</tr>
<tr>
<td>List all executions of a specific mission</td>
<td>GET</td>
<td>.../.../missions/{missions-id}/executions</td>
</tr>
</tbody>
</table>

The Genomic processing configuration API is the most complex one since it includes the definition of the missions and the pipelines steps. Initially, we are supporting simple sequential pipelines, but in the future we plan to introduce the ability to create complex workflows.

Figure 5: PAPAyA processing services.

4.4 User Management

According to the HIPAA regulation, protected health information (PHI) is individually identifiable health information including demographic data (HIPAA, 1996), but also genomic information which is very specific to a particular individual. The disclosure of genomic data can expose details about health status and risks, not only for the patient, but for his relatives as well.

PAPAyA is a tool offered to both clinicians and researchers. While there is a motivation to increase the amount of data to be analysed and processed for clinical trials and research projects, it is imperative to prevent the accidental re-identification of the data and leaks of PHI information from cohort(s) of patients. Frameworks such as GeneCloud (Carey et al., 2014) used by PAPAyA try to address these privacy concerns providing stronger security and privacy guarantees.

The current implementation of PAPAyA is using the Philips HSDP identity and access management (IAM) services. This security façade API enables an application such as PAPAyA to register and log in to HSDP infrastructure by providing end user authentication and authorization based on his/her role (e.g. a researcher does not have the same data access rights as an oncologist or a system administrator).

The HSDP IAM services also provide means to update user profiles, credentials, roles, groups and token management. HSDP logging and auditing
services are also used in tracking suspicious data access transactions, troubleshooting and ensuring regulatory compliance.

5 DEPLOYMENT

Most of the PAPAyA modules are implemented using R/Bioconductor, python and Java/Spring and can be provisioned in a Linux-based container and deployed in a healthcare organization IT data center or in a cloud-based environment.

Through the Philips HSHP PaaS layer, it is possible to provision on-demand access to a shared pool of configurable and elastic computing resources (networks, servers, storage, services) based on the processing needs (Andry et al., 2015).

HSHP runs on top of various types of infrastructure as a service (IaaS) architectures and vendors, including private or public clouds, on-premise, or any hybrid combination.

The fact that PAPAyA is deployed on top of HSHP makes it very scalable. Through service brokering and specific REST APIs, PAPAyA microservices components instance can be scaled up and down on demand extremely quickly and jobs associated to missions and pipelines can be scheduled and run in parallel.

In addition to this, the status of VMS, CPU, memory usage and storage can be monitored and trigger notifications if needed so the DevOps and support teams can make proper adjustments when necessary.

Through the HSHP asynchronous jobs APIs, pipeline steps are deployed and run inside Linux Docker containers, which provide portable, light footprint runtime requirements and extremely quick deployment of managed images. As a result, any genomics tool can be easily integrated as long as they are initially “cloudified”; in other words, able to read/write data inputs/outputs from and to a cloud infrastructure securely and at scale.

6 CONCLUSIONS

Currently, there are 13 million cancer survivors in the US alone and 1.6 million new cases every year. Many new therapies are being introduced (Hal, 2013) that require more detailed knowledge of the genomic makeup of the tumor in order to make a difference in patient outcome. Some of these new therapy agents are in the ballpark of $100,000 per year per patient. While the cost of sequencing has been decreasing, it is still over $1000 to profile a tumor and a normal sample.

To match a targeted therapy with a targeted molecule, a specific genomic candidate aberration must be identified. Many of these aberrations are statistically rare, their real direct effect is unknown, and even after matching, only certain subpopulations of patients may have better outcome. Our platform is capable of learning from each one of these outcomes to put this knowledge back in the service of practicing clinicians.

Our PAPAyA platform for genome analytics, and execution of validated tests, can be used for decision support in clinical practice only when we instantiate modules that perform assessment of genomic aberrations with known clinical significance. In addition, it can serve as the continuous learning platform for cancer research to provide unique value to patient care by deriving more tailored therapy plans, aiding in decisions around aggressiveness of treatment approach, and recommending patients to clinical trials.

As part of the planned extensions of the PAPAyA platform, we would like not only to provide pre-defined workflows for the missions and pipelines via an API, but also the ability for certain advanced users to define these workflows through visual graphic intuitive standards tools, including support for Business Process Model and Notation (BPMN 2.0) processes definition.

ACKNOWLEDGEMENTS

We are very grateful to Patrick Cheung, Yong Mao, Konstantin Volyanskyy, Mine Danisman-Tasar, who have been contributing to this project. Thank you to the PAPAyA R & D team in New York who made this project possible over many years of hard work especially Nilanjana Banerjee, A. Janevski, Vinay Varadan, Sitharthan Kamalakaran. Thank you to the Philips PAPAyA and the hybrid storage teams in Petah Tikva, Israel for help in making PAPAyA a full commercial product. We thank Chad Evans and the HSHP DevOps team for their contribution on asynchronous processing. We are also very grateful to the Iron.io team, especially Chad Arimura for their help with the IronWorker stack.
REFERENCES

Andry, F., Ridolfo, R., Huffman J., 2015, Migrating Healthcare Applications to the Cloud through Containerization and Service Brokering, 8th International Conference on Health Informatics (HealthINF 2015), pp. 164-171, Lisbon, Portugal.


